This inventor holds 1 USPTO granted patent. Top assignee: Aventis Pharma Deutschland, Gmbh. Active years: 2002.
Company Filing History:
Years Active: 2002
Title: Gerald Preibisch: Innovator in Diabetes Treatment
Introduction
Gerald Preibisch is a notable inventor based in Kelkheim, Germany. He has made significant contributions to the field of diabetes treatment through his innovative research and development of pharmaceutical agents.
Latest Patents
Preibisch holds a patent for the "Use of leptin antagonists for treating insulin resistance in type II diabetes." This invention relates to pharmaceutical agents that contain leptin antagonists specifically designed for treating Type II diabetes. One of the leptin antagonists is based on a murine leptin fragment and comprises amino acids 116 to 167 or 116 to 166. The patent also discloses methods for treating Type II diabetes, showcasing his commitment to advancing medical science.
Career Highlights
Gerald Preibisch is associated with Aventis Pharma Deutschland GmbH, where he has been instrumental in developing innovative treatments. His work has focused on addressing critical health issues, particularly in the realm of diabetes management.
Collaborations
Throughout his career, Preibisch has collaborated with esteemed colleagues, including Johann Ertl and Günter Müller. These partnerships have fostered a collaborative environment that enhances the development of effective treatments.
Conclusion
Gerald Preibisch's contributions to diabetes treatment through his patent on leptin antagonists highlight his role as an innovator in the pharmaceutical industry. His work continues to impact the lives of those affected by Type II diabetes.